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Summary Proprotein convertases mediate the production of a variety of peptidic mitogens by limited proteolysis of their precursors. These
proteases may also participate in the autocrine production ofsuch mitogens by cancer cells and thus contribute to the unchecked proliferation
ofthese cells. As a step towards defining this contribution, we have examined the levels of four convertase mRNAs in human lung neoplasms
using semiquantitative Northern blot analysis. Furin mRNA was expressed in all the tumours; its level in squamous cell carcinomas and
adenocarcinomas was on average about threefold higher than in small-cell lung carcinomas (SCLCs). PACE4 transcripts were detected in
eight of 14 adenocarcinomas and in seven of 17 squamous cell carcinomas; they were detectable in only two of seven SCLCs. PC1 mRNA
was undetected in squamous cell carcinomas and in all but two adenocarcinomas; it was present in four of six SCLCs. PC2 mRNA was found
in two adenocarcinomas, in one squamous cell carcinoma and in five of seven SCLCs. This preliminary survey indicates that SCLCs often
carry more mRNA for the endocrine convertases PC1 and PC2 and less mRNA for the more ubiquitous furin and PACE4, suggesting inverse
roles of these convertases in the development of this neoplasm.
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Neoplastic cells often express genes for peptidic growth factors
and their receptors, thus creating an autocrine loop that promotes
their proliferation (Spom and Roberts, 1985). Some lung cancer
cells produce one or several of the following mitogenic peptides:
arginine vasopressin (AVP), neurotensin, ciliary neurotrophic
factor (CNTF), gastrin-releasing peptide (GRP), cholecystokinin
(CCK), neuromedin B (NMB), epidermal growth factors (EGFs)
and galanin (Cook et al, 1993; Moody and Cuttitta, 1993; Bepler
and Garcia-Blanco, 1994). These peptides derive from the proteo-
lytic cleavage of their inactive precursors at sites recognized by
proprotein convertases (PC).
PCs constitute a family of mammalian serine proteases, related
to bacterial subtilisins and to the yeast kexin. Seven of them have
been identified in recent years, namely furin, PACE4, PCI (also
called PC3), PC2, PC4, PC5 (also called PC6) and PC7. These
enzymes cleave their substrates after selected basic amino acids,
mostly after pairs of such residues. Besides growth factors, other
potential and proven substrates include precursors to hornones,
cell-surface receptors and viral glycoproteins (reviewed in Steiner
et al, 1992; Seidah etal, 1993, 1994, 1996; Van de Ven et al, 1993).
Thus, PCs may be intimately involved in the production of many
signalling molecules which, whenabnormally expressedinlungcells,
could lead to their neoplastic transfonnation. If, as we have hypothe-
sized (Mbikay et al, 1993; Chretien et al, 1995), these enzymes are
inactivated somehow in these cancer cells, the cells would be unable
toprocess abattery ofendogenous mitogen precursors to activeforms
and lose theirtransformed phenotype as aconsequence.
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Before arational therapeutic approach based on this concept can
be devised, it is important to determine which PCs are associated
with the major histological types of lung cancer. In this work, we
have examined a collection oflung carcinomas for the presence of
detectable levels offurin, PACE4, PCI and PC2 mRNAs.
MATERIALS AND METHODS
Tissues and cell lines
Surgical lung tumours were obtained from the National Cancer
Institute-sponsored Cooperative Human Tissue Network (CHTN,
Columbus, OH, USA). The tissues were collected at surgery and
were immediately frozen on dry ice and shipped as such. They
were then stored at -80°C. Most of the samples were provided
with a detailed pathology report, including the histological types,
Table 1 Differentiation grades of lung neoplastic samplesa
Lung tumour type n W W-M M M-P P U ?
Adenocarcinoma 14 2 2 (1) 5 (3) 1 3 (2) 0 1
Squamous cell
carcinoma 17 2 (1) 2 3 (2) 3 (2) 9 (1) 1 (1) 0
Small-cell carcinoma 8 0 0 0 0 0 8 0
Others 9 0 0 0 0 1 0 8
aTumour differentiation grades were obtained from the pathology reports
provided with the tissue samples. n, number of patients; W, well
differentiated; W-M, well to moderately differentiated; M, moderately
differentiated; M-P, moderately to poorly differentiated; P, poorly
differentiated; U, undifferentiated;?, unknown grades (no report). The number
of patients in whom lymph node metastases were observed are indicated in
parentheses. Note that all non-SCLC tumours were from primary sites. All
SCLCs were metastases.
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the presence of metastases and prior anti-cancer treatments under-
gone by the patient. Whenever possible, proximal non-malignant
tissue samples were also provided.
The histological types of the 48 surgical lung tumours in this
study and their differentiation grades are shown in Table 1. Few
tumours exhibited a well-differentiated phenotype. Nine of the 14
adenocarcinomas and 15 ofthe 17 squamous cell carcinomas were
moderately to poorly differentiated, whereas all eight SCLCs were
undifferentiated. The nine tumours grouped under 'others' include
one mixed adenosquamous tumour, one giant cell tumour, one
spindle cell neoplasm, one metastatic carcinoma of renal origin,
one metastatic carcinoma of endometrial origin and four untyped
tumours.
Five human lung tumour cell lines, two non-SCLC (NCI-H520,
NCI-H441) and three SCLC (NCI-H82, NCI-H146, NCI-H345)
were obtained from the American Tissue Culture Collection (ATCC,
Rockville, MD, USA) and propagated in culture as recommended.
Molecular biology techniques
Except for the specified modifications, molecular biology tech-
niques were applied following standard protocols (Sambrook et al,
1989; Ausubel et al, 1995).
RNA extraction and Northern blot analysis
Frozen tissues were covered with liquid nitrogen and ground to
powder in a mortar. Cultured cells were rinsed with phosphate-
buffered saline (PBS: 14 mm sodium chloride, 130 mm disodium
hydrogen phosphate, 20 mm sodium dihydrogen phosphate) and
then pelleted by centrifugation. Tissues orcell pellets were homog-
enized in a guanidinium thiocyanate buffer and total RNA was
purified by acid phenol extraction and isopropanol precipitation.
Ten micrograms of this RNA was fractionated by electrophoresis
in a 0.3 M formaldehyde-I% agarose gel in a 50 mM 3-(N-
morpholino)propane sulphonic acid (MOPS) pH 7.0/1 mM EDTA
buffer and transferred by capillarity onto a Nytran-Plus membrane
(Schleicher and Schuell, Keene, NH, USA). The membrane was
preincubated at 68°C in a buffer containing 0.1% bovine serum
albumin, 5% sodium dodecyl sulphate (SDS), 50% formamide and
400 mm sodium phosphate buffer, pH 7.2, for 1-6 h. A 32P-labelled
cRNA probe (specific activity 1-3 x 109 d.p.m. ug-') was added to
the buffer and incubation was continued for 16 h. The membrane
was washed at 75°C three times for 15 min in 0.1% SDS/15 mM
sodium chloride/1.5 mm sodium citrate/I mm EDTA; it was
exposedovernight to aphosphorimaging plate and then to a Kodak
XAR-5 film for 1-7 days.
The 24-h signals on the plates were analysed on a phosphor
imager (Molecular Dynamics, Sunnyvale, CA, USA) and the pixel
values of hybridization bands were collected for quantification.
When comparing values from different convertase probes, correc-
tion factors were introduced to account for differences in probe
length and specific activity. Reference lung RNAs were used in
each blot analysis to normalize the hybridization signals for a
particular probe on different membranes.
Probes
cDNA fragments for human convertases in the pSP72 plasmid
(Fisher/Promega, Nepean, Ontario, Canada) were used for in vitro
biosynthesis of [32P]cRNA probes. Based on the complete cDNA
sequences found in the GenBank database, the nucleotide (nt)
ranges of the cDNA probes were: nts 130-980 for furin, nts
1185-1465 for PACE4, nts 2560-3298 forPCI and nts 1734-1924
for PC2. Each plasmid was linearized by a single-site digestion, 5'
end to the cDNA fragment; the latter was then transcribed into
cRNA from the flanking SP6 or T7 promoter using the corres-
ponding RNA polymerase in the presence of [a-32P]UTP.
Membranes were also probed for the 18S ribosomal RNA with a
5'-32P-labelled, 29-nt-long synthetic oligodeoxynucleotide. The
hybridization time was reduced to 7 h; the temperature for both
hybridization and washing was 42°C.
Western blot for PC2 in SCLCs
Tissue powders (0.5 g) or cell pellets (5 x 108 cells) were
suspended in 0.3 ml of an ice-cold buffer made of0.1 M Tris HCl,
pH 7.4, 2.5 mM EDTA, 10 gM pepstatin A, 10 ,UM leupeptin and
2.5 mM phenymethylsulphonyl fluoride (PMSF); the suspension
was sonicated at 4°C with 3-6 15-s bursts of sonicator probe. The
homogenates were cleared by centrifugation at 100 000 g and 4°C
for 2 h. The protein content in the supernatants was determined
using the Bradford's dye method (Bradford, 1976). Supernatant
proteins (20 ,ug per lane) were subjected to electrophoresis in an
Table 2 Incidence and levels of convertase mRNAs in non-malignant and neoplastic lung samplesa
Surgical samples Cell lines
Non- Adenocarcinoma Squamous cell SCLC Others SCLC Non-
malignant carcinoma SCLC
Furin .... .... .... + to ++ ++
(27/27) (14/14) (17/17) (8/8) (9/9) (3/3) (2/2)
PACE4 ++ ++ ++ + +to ++ - to ++
(24/17) (8/14) (7/7) (2/7) (9/9) - (2/2)
PC1 ±to+ ±to+ - +to++ - ++ -
(2/27) (2/14) _ (4/6) - (1/3) -
PC2 ±to + ±to ++ ±to + ++ to+++ to + + to+++ -
(8/27) (2/14) (1/17) (5/7) (2/9) (3/3) N
aThe relative mRNA abundance was estimated as described in Materials and methods, using the average level of furin in non-malignant samples as reference:
-, undetectable; ±, very low levels; +, low levels; ++ moderate levels; ++++, high levels. Given in parentheses are the numbers of positive samples for a
particular mRNA over the total number of samples of the same histological type examined.
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Figure 2 Western blot analysis of PC2 expression in SCLCs. (A) Surgical SCLC (T) and non-malignant (N) samples. (B) NCI-H human lung tumour cell lines.
Brackets indicate that the N and T samples were from the same patient
Table 3 Furin levels in homonymous non-malignant and neoplastic tissuesa
Tumourtypes n TcN T=N T,N
Adenocarcinoma 7 0 4 3
Squamous cell carcinoma 11 1 10 0
Others 9 0 9 0
aNeoplastic (T) and non-malignant (N) tissues from individual patients were
compared for the level of furin mRNA. The total number of pairs are shown
under n. Scoring categories: < or > indicates a twofold minimal difference
between T and N; = indicates no difference or a less than twofold difference.
SDS-poly.acrylamide gel and then transferred to an Immobilon-P
membrane (Millipore, Nepean, Ontario, Canada); this membrane
was incubated at room temperature with a rabbit antibody against
PC2 (Benjannet et al, 1993), then with biotinylated goat IgG
against rabbit IgGs and finally with streptavidin horseradish
peroxidase. The immune complex was revealed using a luminol-
based chemoluminescence detection kit (Amersham, Arlington
Heights, IL, USA). This Western blot protocol has been described
in more detail by Linard et al (1995).
RESULTS
Convertase mRNAs in lung tumours
Figure 1 shows representative Northern blot results for adenocar-
cinomas (Figure IA), squamous cell carcinomas (Figure IB),
SCLCs (Figure IC), and lung tumour cell lines (Figure ID). All
the samples were probed for their content in mRNAs for furin,
PACE4, PCI and PC2 and for the 18S rRNA, this serving as an
internal standard to correct for differences in amounts of total
RNAs loaded onto the blots. All the RNAs were ofrelatively good
quality as judged by the lack of extensive smearing below the
hybridizing bands. These bands were ofthe expected sizes, except
for PACE4 mRNA in the cell lines NCI-H146 and NCI-H345, for
which a 9.2-kb isoform was detected (Figure ID).
The incidence and the relative abundance ofconvertase mRNAs
in the lung tissues are summarized in Table 2. Furin mRNA was
present in all the tissues examined. However, based on overnight
autoradiographic signals following equivalent hybridization
conditions, this mRNA was on average three times more abundant
in non-SCLC samples (non-malignant tissues, adenocarcinomas or
squamous cell carcinomas) than in SCLCs (compare Figure lA
and lB with Figure IC).
PACE4 mRNA, when present, was in lower amounts than furin
mRNA and a 7-day exposure of the blot to radiographs was
required to obtain a good hybridization signal. It was detectable in
nearly all non-malignant tissues, but in only 17 ofthe 38 classified
solid tumours, with all classes combined. Its level was noticeably
lower in most SCLCs (see Figure IC).
PC1 mRNA was detected in four of six SCLCs. Except for two
non-malignant tissues and two adenocarcinomas, the other lung
cancer tissues did not contain detectable amounts ofthe PC1 mRNA.
Among the five established lung carcinoma cell lines analysed, only
the SCLC NCI-H345 was found to express PCI mRNA (Figure ID).
PC2 mRNA was found in small amounts in about a third of the
non-malignant tissues and it was clearly more abundant in five of
seven SCLCs (see Figure IC). PC2 mRNA was detected in two
adenocarcinomas and in one squamous cell carcinoma. It was also
present in the SCLC cell lines NCI-H82, NCI-H146 and NCI-
H345 (Figure ID) but was undetectable in the non-SCLC lines
NCI-H520 (Figure ID) and NCI-H441 (not shown).
The lung tumours grouped under 'others' all contained furin and
PACE4 mRNAs. PC2 mRNA was found in two of these tumours;
PCI mRNA in none.
Some lung tumour samples were provided with a sample of the
proximal non-malignant lung tissue as controls. These corres-
ponding samples were compared for their furin content. The
results indicate that, relative to controls, the level of furin mRNA
generally remained unchanged in squamous cell carcinomas; it
was also unchanged in three of the seven adenocarcinomas exam-
ined and present at higher level in the other four (Table 3).
PC2 protein in SCLCs
The elevated content of PC2 mRNA in some SCLCs led us to
examine whether the PC2 protein was also easily detectable in
these tumours and under what molecular forms. The results are
shown in Figure 2. PC2 immunoreactive protein bands were
observed in four of the five SCLCs examined. In one sample
(Figure 2A, lane 1), the 68-kDa active PC2 form was more abun-
dant than the 72-kDa intermediate form. Note that the immuno-
reactive bands in this sample were relatively weak, considering the
high levels of PC2 mRNA it contained (see Figure IC, lane 1). In
the other three samples (Figure 2A, lanes 2, 3 and 5), the 72- and
the 68-kDa forms of PC2 were present in nearly equivalent
amounts, and the overall intensities of the protein bands were in
good correlation with the relative abundance of the mRNA (see
Figure IC, lanes 2, 3 and 5).
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PC2 immunoreactive bands were detected in the SCLC cell
lines NCI-H146 and NCI-H345 (Figure 2B, lanes 2 and 3); they
were absent in the SCLC line NCI-H82 and in the two non-SCLC
lines (Figure 2B, lanes 1,4 and 5). In the NCI-H345 cells, in which
PC2 mRNA is particularly abundant (see Figure ID, lane 3), the
75-kDa proPC2 was observed in addition to the 72- and 68-kDa
processed forms.
DISCUSSION
In this study, we have screened a collection oflung tumours for the
presence of four convertase mRNAs. The results indicate that the
genes for these enzymes are expressed in various combinations
and in differing amounts.
Furin mRNA was found in nearly all the tissues examined. In
general, the levels of this mRNA were higher in non-malignant
human tissues, in adenocarcinomas and in squamous cell carci-
nomas than in SCLCs (Figure 1 and Table 1). In some adenocarci-
nomas, it was three to five times higher than in their proximal
non-malignant tissues. Such adifference was not observed in squa-
mous cell carcinomas (Table 3). Low levels of furin mRNA in
SCLCs were also reported by Schalken et al (1987). However,
unlike us, these authors observed very little furin mRNA in non-
malignant human lung tissues, but 10-25 times more in most
adenocarcinomas and in squamous cell carcinomas. The reason for
this difference is unclear. It may be that the furin gene expression
was somehow up-regulated in the control samples examined in our
study which, in each case, represented non-malignant tissues
surrounding the tumour.
This is the first report of PACE4 mRNA expression in human
lung tissues. It was found in nearly all non-malignant lung tissues
and in about half of the bronchogenic tumours, all classes
combined. When detectable, this mRNA was generally found in
low amounts, most strikingly so in SCLCs (Figure 1 and Table 2).
Other studies have also shown that PACE4 mRNA is not highly
expressed in lung tissues (Kiefer et al, 1991; Seidah et al, 1994).
PCI and PC2 are primarily expressed in neuronal and endocrine
cells (Seidah et al, 1991). As expected, the incidence of their
mRNAs was higher among SCLCs, which exhibit a neuro-
endocrine phenotype (Linnoila et al, 1988), than among adenocar-
cinomas and squamous cell carcinomas (Figure 1 and Table 1).
These data support the proposed use of PCI and PC2 as discrimi-
natory indicators of neuroendocrine differentiation of neoplastic
tissues (Creemers et al, 1992; Scopi et al, 1995)
We did not observe any correlation between the differentiation
or the metastatic character of the primary tumours and the pattern
or the level ofconvertase expression.
A major goal of our research is to verify the hypothesis that
inhibiting expression of certain key convertases may disrupt the
autocrine loop that promotes lung cancer cell proliferation. Our
efforts are focused on SCLCs, which represent the most aggressive
form of this neoplasm. This survey of convertase expression in
SCLCs strongly suggests that PCI and PC2 are the two conver-
tases most likely to play a role in the maintenance ofthe neoplastic
phenotype ofthese cells. They would be involved in the activation
of several ofthe various precursors to growth factors produced by
the cells, such as AVP, GRP, EGF and CCK (Cook et al, 1993;
Moody and Cuttitta, 1993; Bepler and Garcia-Blanco, 1994); it has
been suggested that the release ofsmall bioactive peptides, such as
these, from their precursors is mediated by PC2 (Dupuy et al,
1994; Seidah and Chretien, 1994). PC2 has been implicated in the
conversion of proGRP to GRP (Dickinson et al, 1995).
We plan to use established human SCLC cell lines as model
systems to test the hypothesis. The NCI-H345 and NCI-H146 cell
lines express the 68-kDa active isoform of PC2 and could be used
to that end. We have also analysed these cell lines for the presence
ofGRP transcripts and immunoreactivity. GRP mRNA and protein
were detectable in NCI-H345 cells only. NCI-H146 cells, which
are relatively PC2 rich (see Figures ID and 2B), were negative for
both macromolecules (data not shown).
Proteases may promote carcinogenesis as their inhibitors are
anti-cancer agents (Kennedy, 1994). Serine proteases are also
found among these presumed cancer-promoting proteolytic
enzymes. Clark et al (1993) have shown that the Bowman-Birk
inhibitor (BBI), which affects trypsin/chymotrypsin-type serine
proteases, can block in vitro clonal growth of NCI-H345 cells.
Growth inhibition by BBI was associated with a reduction of
proGRP processing to GRP and, most interestingly, could be
reversed by adding exogenous GRP to the culture medium. BBI
treatment also caused a 50% reduction of PCI and PC2 mRNA,
suggesting a pleotropic effect by this agent. It is unclear from this
study whether BBI was actually blocking the enzymatic activity of
PCI or PC2. Moreover, it is probable that this inhibitor acts on a
whole battery of other serine proteases. A more selective inhibi-
tion, by anti-PC1 or anti-PC2 antisense nucleic acids for example,
could shed more light on the relative importance of each enzyme
for SCLC neoplasticity. For example, it will be interesting to deter-
mine whether specific inactivation of PC2 in NCI-H345 cells
would prevent proGRP activation and thus block cell proliferation.
It is noteworthy that the levels of furin and PACE4 mRNAs are
generally very low in SCLC samples. The low level of furin
concords with the neuroendocrine phenotype of these cells, as this
enzyme is also found in low amounts in neuronal cells (Schalken
et al, 1987; Seidah et al, 1994). PACE4 mRNA, on the other hand,
seems to be expressed in good amounts in normal neuroendocrine
tissues (Kiefer et al, 1991; Seidah et al, 1994). Whether its reduced
expression in SCLC cells is contributing to the transformed pheno-
type of these cells (e.g. is PACE4 a tumour suppressor?) could
eventually be verified by studying the consequence of PACE4
transgene expression for this phenotype.
There are seven reported convertases to date and the expression
of only four has been examined here. PC4 was not considered
because it is a germline-specific convertase (Seidah et al, 1992).
Expression ofPC5 and PC7 remains to be studied.
Obviously, this analysis needs to be extended to a large panel of
lung tumours for a stronger correlation. A tentative conclusion of
this preliminary survey is that PC2 could be a good target for inac-
tivation in the treatment of SCLCs. The conclusion is reinforced
by the current state of knowledge of the enzymatic properties and
the substrate specificity of this convertase (Seidah and Chretien,
1994). Experiments with PC2-selective inhibitors (i.e. antisense
oligonucleotides and genes) are under way to verify this hypoth-
esis in cultured or transplanted SCLC cells.
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